News | July 22, 2023
Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin
Good momentum in commercial CDMO business
Good momentum in commercial CDMO business
CMOs showed an increasing reluctance to take on debt in 2022
Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications
First of its kind screening for Glaucoma at grass root level over 10k screened already
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
